ARMISTICE CAPITAL LLC
Q4 2022 Form 13-F

NEW YORK, NEW YORK
CIK 0001601086 · CRD 168978 · SEC-registered investment adviser
$5.7B Reported Value Total

ARMISTICE CAPITAL LLC reports 3 total accounts under management (AUM). There are 3 discretionary accounts valued at $5,555,432,880, and 0 non-discretionary accounts.

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered Discretionary Manager
Private funds (Form ADV)
1 fund · $4.7B gross asset value
Hedge Fund: $4.7B
Source: Form ADV filed 2026-03-31
Reported value
$5.7B
Quarter over quarter
+14.0%
Holdings
191
Top-10 concentration
53.0%

Filing Structure

Reports holdings for

  • Armistice Capital Master Fund Ltd. (not a 13F filer in our records) · File #028-16739 · Q4 2014 – Q1 2021

Key People

Form ADV owners & control persons
Steven Joseph Boyd
MANAGING MEMBER
Jose Yldefonso Mallonga Bautista
CHIEF COMPLIANCE OFFICER AND DEPUTY CHIEF FINANCIAL OFFICER
Anthony Joseph Cordone
CHIEF FINANCIAL OFFICER

Filing Navigation

13F Metrics

Loading 13F Metrics

Q4 2022 13F record

Q4 2022 13F filing summary

Q4 2022 Form 13F portfolio summary
Period of report December 31, 2022
Filed February 14, 2023
Form 13F-HR
Reported value $5.7B
Positions 191
Change in reported value -0.6%
New positions 64
Exited positions 67
Position turnover 50.8%
Top-10 concentration 53.0%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2026 13F
Filed Nov 16, 2026
333 $8.2B
Q2 2026 13F
Filed Aug 14, 2026
323 $8.2B
Q1 2026 13F
Filed May 15, 2026
251 $5.6B
Q4 2025 13F
Filed Feb 17, 2026
357 $8.4B
Q3 2025 13F
Filed Nov 17, 2025
318 $6.7B
Q2 2025 13F
Filed Aug 14, 2025
200 $5.8B
Q1 2025 13F
Filed May 15, 2025
220 $6.7B
Q4 2024 13F
Filed Feb 14, 2025
227 $7.3B
Q3 2024 13F
Filed Nov 14, 2024
254 $6.3B
Q2 2024 13F
Filed Aug 14, 2024
250 $7.9B
Q1 2024 13F
Filed May 15, 2024
333 $7.5B
Q4 2023 13F
Filed Feb 13, 2024
290 $7.3B
Q3 2023 13F
Filed Nov 14, 2023
250 $6.5B
Q2 2023 13F
Filed Aug 14, 2023
218 $6.9B
Q1 2023 13F
Filed May 15, 2023
223 $6.9B
Q4 2022 13F
Filed Feb 14, 2023
191 $5.7B
Q3 2022 13F
Filed Nov 14, 2022
194 $5.8B
Q2 2022 13F
Filed Aug 15, 2022
175 $5.7B
Q1 2022 13F
Filed May 16, 2022
139 $5.2B
Q4 2021 13F
Filed Feb 14, 2022
143 $6.1B

28 earlier quarters on file — choose one from the quarter menu above.

Top 20 holdings · Q4 2022

Largest Q4 2022 13F positions by reported value
# Holding Reported value % of portfolio
1 SPY P SPDR S&P 500 ETF TR $1.3B 22.35%
2 IWM P ISHARES TR $732.3M 12.78%
3 MRTX MIRATI THERAPEUTICS INC $158.0M 2.76%
4 SUPN SUPERNUS PHARMACEUTICALS INC $155.4M 2.71%
5 TVTX TRAVERE THERAPEUTICS INC $134.8M 2.35%
6 PTCT PTC THERAPEUTICS INC $129.6M 2.26%
7 INCY INCYTE CORP $113.4M 1.98%
8 FRPT FRESHPET INC $112.7M 1.97%
9 BIIB BIOGEN INC $110.8M 1.93%
10 NBIX NEUROCRINE BIOSCIENCES INC $107.5M 1.88%
11 GSK GSK PLC $107.4M 1.87%
12 AMZN AMAZON COM INC $97.8M 1.71%
13 ENTA ENANTA PHARMACEUTICALS INC $96.7M 1.69%
14 GOOGL ALPHABET INC $86.1M 1.5%
15 DCPH DECIPHERA PHARMACEUTICALS IN $84.8M 1.48%
16 REGN REGENERON PHARMACEUTICALS $79.4M 1.38%
17 AGIO AGIOS PHARMACEUTICALS INC $77.2M 1.35%
18 EXAS EXACT SCIENCES CORP $76.0M 1.33%
19 ALKS ALKERMES PLC $75.8M 1.32%
20 PCRX PACIRA BIOSCIENCES INC $73.1M 1.27%

Values as reported on the Q4 2022 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings